For the six months ended March 2027, consolidated net sales were 19,974 million yen, down 6.5% year-over-year. Operating loss was 3,504 million yen, ordinary loss was 3,798 million yen, and net loss attributable to owners of the parent was 3,867 million yen. R&D expenses increased by 30.6%. A dividend of 10 yen was paid at the end of the second quarter; full-year forecast is 20 yen. There is no change to the full-year outlook for the fiscal year ending March 2027 as previously announced.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4552-20261029-02.pdf","jir_short_summary":"For the six months ended March 2027, consolidated net sales were 19,974 million yen, down 6.5% year-over-year. Operating loss was 3,504 million yen, ordinary loss was 3,798 million yen, and net loss attributable to owners of the parent was 3,867 million yen. R&D expenses increased by 30.6%. A dividend of 10 yen was paid at the end of the second quarter; full-year forecast is 20 yen. There is no change to the full-year outlook for the fiscal year ending March 2027 as previously announced.","jir_summary":"### Overview of Results\nNet sales for the interim period were 19,974 million yen, a 6.5% decrease year-over-year. The primary reasons were a decline in contract fee income and reduced revenue from the Grow project. A significant increase in research and development expenses led to an operating loss. Ordinary loss also widened, resulting in an interim net loss of 3,867 million yen. Segment information is omitted because the pharmaceutical business constitutes a single reportable segment.\n\n### Future Capital Policy and Financial Position\nCash and cash equivalents have decreased, total assets and liabilities have increased, and the equity ratio declined by 7.0 percentage points. A commitment line agreement totaling 49,500 million yen has been arranged as a backup; of this, 26,500 million yen is planned to be allocated for financing a new formulation manufacturing plant. Cash flow was negative from operating activities, significant outflows for investing activities, and a notable net increase in borrowings in financing activities.","jir_financial_highlights":"Net Sales: 19,974 (Year-over-Year -6.5%)\nOperating Income: -3,504 (Year-over-Year -)\nOrdinary Income: -3,798 (Year-over-Year -)\nNet Income Attributable to Owners of Parent (Interim): -3,867 (Year-over-Year -)\nEquity Ratio: 35.9 (Compared to Fiscal Year-End -7.0pt)","jir_category":"","jir_hashtags":"#JCRPharmaceuticals, #Earnings, #InterimResults","jir_key_figures":"Net Sales: 19,974 million yen\nOperating Loss: -3,504 million yen\nOrdinary Loss: -3,798 million yen","jir_meta_title":"JCR Pharmaceuticals Co., Ltd. - Key Points and Outlook for 2Q Results | October 2026","jir_meta_description":"Summary of JCR Pharmaceuticals' financial summary for the second quarter of the fiscal year ending March 2027. Net sales were 19,974 million yen, operating loss was 3,504 million yen; review of increased R&D expenses, dividend policy, and capital strategy.","jir_og_title":"JCR Pharmaceuticals Co., Ltd. - Key Points and Outlook for 2Q Results","jir_og_description":"JCR Pharmaceuticals' interim results show a decline in net sales and widening losses. Key points on increased R&D spending, financial position, and capital policy are summarized.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-136610","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n